(dtpa-phe(1))-octreotide and Acromegaly

The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs. They were first used to treat acromegaly in the mid 1980s and numerous studies have shown a reduction in GH concentration in over 90% of acromegalic patients. Good results were obtained using slow-release analog treatment also in TSH-secreting adenomas, whereas the therapeutic efficacy of these peptides in clinically non-functioning adenomas is still controversial. Treatment with somatostatin analogs improves symptoms, normalises hormone secretion and in some cases may induce a reduction in the volume of pituitary adenomas. Scintigraphy with octreotide may help to select patients who respond to this form of treatment.

Topics: Acromegaly; Adenoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents, Hormonal; Carcinoma; Humans; Indium Radioisotopes; Insulin-Like Growth Factor I; Kidney Neoplasms; Melanoma; Middle Aged; Octreotide; Pentetic Acid; Peptides, Cyclic; Pheochromocytoma; Pituitary Neoplasms; Predictive Value of Tests; Prolactinoma; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Somatostatin; Thymoma; Thymus Neoplasms; Thyroid Neoplasms; Thyrotropin; Treatment Outcome